Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer TreatmentGlobeNewsWire • 10/13/21
Lixte Biotechnology's LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine AddictionGlobeNewsWire • 08/17/21
Lixte Biotechnology Shares Are Trading Higher On Encouraging Preclinical LB-100 Data In Lung CancerBenzinga • 08/03/21
LIXTE BIOTECHNOLOGY'S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDYGlobeNewsWire • 08/03/21
LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISMGlobeNewsWire • 07/22/21
Lixte Biotechnology Comments on Outside Research Citing LB-100's PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast CancerGlobeNewsWire • 07/13/21
Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021GlobeNewsWire • 07/07/21
Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung CancerGlobeNewsWire • 06/02/21
LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORSGlobeNewsWire • 05/12/21
Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20GlobeNewsWire • 05/04/21
Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of DirectorsGlobeNewsWire • 04/13/21
Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital ConferenceGlobeNewsWire • 03/03/21
WestPark Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)Business Wire • 03/02/21
WallachBeth Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc.PRNewsWire • 03/02/21
Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct OfferingGlobeNewsWire • 03/02/21
Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences ConferenceGlobeNewsWire • 02/24/21
Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte's Lead Compound LB-100 to Treat Small Cell Lung CancerGlobeNewsWire • 01/19/21